Digital phenotyping reveals discordance between clinical guidelines and patient satisfaction in premenstrual dysphoric disorder - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Digital Phenotyping Highlights a Gap Between Clinical Guidelines and Patient Satisfaction in Premenstrual Dysphoric Disorder

  • By

  • Hassan Jubair

  • Md Abu Kawsar Prodhan Hemal

  • Fariah Tabbasum

  • October 15, 2026

Share

  • 1

    PMDD affects approximately 3% to 8% of menstruating individuals and can involve severe dysphoria, suicidal ideation, and impaired social and functional well-being.

  • 2

    SSRIs and oral contraceptives are described as gold-standard PMDD treatments, but adverse effects can contribute to discontinuation and dissatisfaction.

  • 3

    The study used retrospective digital ethnography and natural language processing to analyze 1,491 unique narratives from the public r/PMDD subreddit.

  • 4

    Narratives were classified as SSRI treatment (n = 317), hormonal interventions (n = 309), nutritional or holistic supplements (n = 239), or off-label antihistamines (n = 11).

  • 5

    The study aimed to assess treatment satisfaction and tolerability in a digitally native, help-seeking population; the provided context does not report its results.

Original Source(s)

Related Content